5-(5-bromo-2,4-dimethoxyphenyl)oxazole | 1091618-42-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-(5-bromo-2,4-dimethoxyphenyl)oxazole
• CAS: 1091618-42-6
• 化学式: C₁₁H₁₀BrNO₃
• 分子量: 284.109
• InChiKey: OXNWQDKQKGNQSR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.12
• 重原子数：
  16.0
• 可旋转键数：
  3.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  44.49
• 氢给体数：
  0.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  5-(5-bromo-2,4-dimethoxyphenyl)oxazole 在 trans-N,N'-dimethyl-1,2-cyclohexyldiamine 、 copper(l) iodide 、 sodium iodide 作用下， 以 1,4-二氧六环 为溶剂， 反应 24.0h， 以92%的产率得到
  参考文献：
  名称：

  Mycophenolic acid analogs with a modified metabolic profile

  摘要：

  Mycophenolic acid (MPA), a clinically used immunosuppressant, is extensively metabolized into an inactive C7-glucuronide and removed from circulation. To circumvent the metabolic liability imposed by the C7-hydroxyl group, we have designed a series of hybrid MPA analogs based on the pharmacophores present in MPA and new generations of inosine monophosphate dehydrogenase (IMPDH) inhibitors. The synthesis of MPA analogs has been accomplished by an allylic substitution of a common lactone. Biological evaluations of these analogs and a preliminary structure-activity relationship (SAR) are presented. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2008.08.062
• 作为产物：
  描述：

  对甲基苯磺酰甲基异腈 、 5-溴-2,4-二甲氧基苯甲醛 在 potassium carbonate 作用下， 以 甲醇 为溶剂， 反应 22.0h， 以95%的产率得到5-(5-bromo-2,4-dimethoxyphenyl)oxazole
  参考文献：
  名称：

  Mycophenolic acid analogs with a modified metabolic profile

  摘要：

  Mycophenolic acid (MPA), a clinically used immunosuppressant, is extensively metabolized into an inactive C7-glucuronide and removed from circulation. To circumvent the metabolic liability imposed by the C7-hydroxyl group, we have designed a series of hybrid MPA analogs based on the pharmacophores present in MPA and new generations of inosine monophosphate dehydrogenase (IMPDH) inhibitors. The synthesis of MPA analogs has been accomplished by an allylic substitution of a common lactone. Biological evaluations of these analogs and a preliminary structure-activity relationship (SAR) are presented. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2008.08.062